Ayahuasca & MAOI
Ayahuasca is a psychoactive brew traditionally used by indigenous peoples of the Amazon for spiritual and medicinal purposes. It contains two primary components: the Banisteriopsis caapi vine, which provides beta-carboline alkaloids (such as harmine, harmaline, and tetrahydroharmine), and the leaves of a plant like Psychotria viridis or Diplopterys cabrerana, which contain the hallucinogenic compound dimethyltryptamine (DMT).
The primary mechanism through which Ayahuasca exerts its effects involves the interaction between DMT and monoamine oxidase inhibitors (MAOIs) found in the B. caapi vine. DMT is a powerful psychedelic that is normally broken down rapidly in the gut and liver by monoamine oxidase (MAO) enzymes, rendering it inactive when taken orally. However, the beta-carboline alkaloids in B. caapi inhibit the action of these enzymes, allowing DMT to enter the bloodstream and cross the blood-brain barrier. Once in the brain, DMT acts as an agonist at serotonin 5-HT2A receptors, which are key to the generation of the profound visual and emotional experiences associated with Ayahuasca.
The beta-carbolines in the vine also have psychoactive properties. They exhibit their own MAO-inhibitory effects and are thought to contribute to the brew's overall psychoactive profile by modulating serotonin, dopamine, and GABA systems. They may also influence neuroplasticity and exhibit antioxidant properties, potentially offering therapeutic benefits.
The subjective effects of Ayahuasca include vivid visual imagery, alterations in perception, introspection, emotional breakthroughs, and often a sense of spiritual connection. These experiences are thought to result from the combined action of DMT and the beta-carbolines on neural circuits related to sensory processing, emotional regulation, and self-referential thought.
On a physiological level, Ayahuasca can induce nausea, vomiting, and diarrhea, which are often described as part of the purging process. These effects may be due to its actions on serotonin receptors in the gut. Users also typically experience changes in heart rate and blood pressure due to the interaction of the brew's compounds with the autonomic nervous system.
Neurobiologically, Ayahuasca has been shown to influence connectivity within and between various brain networks, such as the default mode network (DMN), which is associated with self-referential thought and the sense of ego. The reduction in DMN activity, coupled with increased connectivity between sensory and emotional brain regions, may underlie the ego-dissolving and transformative aspects of the experience.
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that work by inhibiting the activity of the monoamine oxidase (MAO) enzymes, which are responsible for breaking down monoamines in the brain and other tissues. Monoamines are neurotransmitters such as serotonin, dopamine, and norepinephrine, which play key roles in regulating mood, arousal, and other physiological processes. By inhibiting the breakdown of these neurotransmitters, MAOIs increase their availability in the synaptic cleft, leading to enhanced signaling between neurons.
The MAO enzyme exists in two main forms: MAO-A and MAO-B. MAO-A preferentially metabolizes serotonin, norepinephrine, and epinephrine, while MAO-B primarily metabolizes phenylethylamine and certain other substrates. Both forms metabolize dopamine, though to differing extents. MAOIs can be selective or non-selective in their action, targeting one or both isoforms. For example, phenelzine and tranylcypromine are non-selective MAOIs that inhibit both MAO-A and MAO-B, while moclobemide is a selective inhibitor of MAO-A, and selegiline selectively inhibits MAO-B at low doses.
When MAOIs inhibit these enzymes, they prevent the degradation of monoamines within the presynaptic neuron and mitochondria, allowing more of these neurotransmitters to accumulate. This increase can improve synaptic transmission and alleviate symptoms of mood disorders, such as depression, which are often associated with reduced levels of serotonin, norepinephrine, or dopamine.
The effects of MAOIs extend beyond neurotransmitter metabolism. For instance, MAO-A inhibition can increase serotonin levels, improving mood and reducing anxiety, while MAO-B inhibition can increase dopamine levels, which may help in treating neurodegenerative conditions such as Parkinson's disease. Selegiline, for example, is used to manage Parkinson's by increasing dopamine levels in the brain, particularly in the striatum, where dopamine-producing neurons are lost.
Combining ayahuasca with MAOIs can significantly amplify both the desired and adverse effects of the brew. Ayahuasca itself contains natural MAOIs, primarily harmine and harmaline, which inhibit the breakdown of DMT, allowing it to become orally active. Introducing external MAOIs, whether pharmaceutical or from other plant sources, can lead to several potential outcomes.
Firstly, the psychoactive effects of ayahuasca may be intensified. The additional inhibition of monoamine oxidase can result in higher concentrations of DMT and other monoamines in the brain, leading to more profound hallucinations, emotional experiences, and alterations in perception. This heightened state can be overwhelming and may increase the risk of psychological distress, including anxiety, paranoia, or panic attacks.
Secondly, the risk of serotonin syndrome is elevated. Serotonin syndrome is a potentially life-threatening condition caused by excessive accumulation of serotonin in the central nervous system. Symptoms include agitation, confusion, rapid heart rate, fluctuating blood pressure, dilated pupils, muscle rigidity, and in severe cases, seizures or loss of consciousness. The combination of ayahuasca and additional MAOIs can lead to dangerously high serotonin levels, especially if other serotonergic substances are also present.
Thirdly, there is an increased likelihood of hypertensive crises. MAOIs inhibit the breakdown of tyramine, a naturally occurring amino acid found in various foods and beverages. Elevated tyramine levels can cause a sudden and dangerous increase in blood pressure. When combining ayahuasca with other MAOIs, strict dietary restrictions are necessary to avoid high-tyramine foods such as aged cheeses, cured meats, fermented products, and certain alcoholic beverages. Failure to adhere to these restrictions can result in severe headaches, chest pain, and potential cardiovascular complications.
Additionally, the combination can lead to prolonged and unpredictable pharmacological effects. The metabolism of DMT and other psychoactive compounds may be further inhibited, leading to extended duration of action and unpredictable intensity of effects. This can complicate the ayahuasca experience, making it more difficult to manage and increasing the potential for adverse reactions.
Furthermore, the combination may exacerbate gastrointestinal disturbances. Ayahuasca commonly induces nausea, vomiting, and diarrhea, which are often considered part of the purging process. Additional MAOIs can intensify these effects, leading to dehydration, electrolyte imbalances, and increased physical discomfort.
Given these significant risks, such combinations are generally discouraged, and individuals are advised to approach ayahuasca use with caution, under the guidance of experienced practitioners and with full awareness of potential interactions.
All things considered, we recommend avoiding this combination.
Last edited by a moderator: